Trial · NCT00667823
Results by group13
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 13 of 13
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to 28 Days After Study Treatment Discontinuation | Macitentan 10 mg | 527 | Participants | ||
| Number of Participants With Death up to 28 Days After Study Treatment Discontinuation | Macitentan 10 mg | 175 | Participants | ||
| Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs) up to 28 Days After Study Treatment Discontinuation | Macitentan 10 mg | 354 | Participants | ||
| Number of Participants With AEs Leading to Permanent Discontinuation of Study Treatment | Macitentan 10 mg | 62 | Participants | ||
| Number of Participants With Treatment Emergent Abnormal Liver Tests up to 28 Days After Study Treatment Discontinuation | Macitentan 10 mg | ALT or AST >3*ULN | 45 | Participants | |
| Number of Participants With Treatment Emergent Abnormal Liver Tests up to 28 Days After Study Treatment Discontinuation | Macitentan 10 mg | ALT or AST >5*ULN | 20 | Participants | |
| Number of Participants With Treatment Emergent Abnormal Liver Tests up to 28 Days After Study Treatment Discontinuation | Macitentan 10 mg | ALT or AST >8*ULN | 11 | Participants | |
| Number of Participants With Treatment Emergent Abnormal Liver Tests up to 28 Days After Study Treatment Discontinuation | Macitentan 10 mg | TBIL >2*ULN | 75 | Participants | |
| Number of Participants With Treatment Emergent Abnormal Liver Tests up to 28 Days After Study Treatment Discontinuation | Macitentan 10 mg | ALT or AST >3*ULN and (TBIL>2*ULN at any time) | 8 | Participants | |
| Number of Participants With Treatment Emergent Hemoglobin Abnormality up to 28 Days After Study Treatment Discontinuation | Macitentan 10 mg | HGB <= 80 gram/Liter (g/L) | 33 | Participants | |
| Number of Participants With Treatment Emergent Hemoglobin Abnormality up to 28 Days After Study Treatment Discontinuation | Macitentan 10 mg | HGB <= 100 g/L | 98 | Participants | |
| Number of Participants With Treatment Emergent Hemoglobin Abnormality up to 28 Days After Study Treatment Discontinuation | Macitentan 10 mg | HGB decrease from baseline >= 20 g/L | 188 | Participants | |
| Number of Participants With Treatment Emergent Hemoglobin Abnormality up to 28 Days After Study Treatment Discontinuation | Macitentan 10 mg | HGB decrease from baseline >= 50 g/L | 29 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00667823/results